Pharmaceuticals
Hillhouse buys Australia CRO George Clinical
Hillhouse Capital has agreed to buy George Clinical, an Australia-based clinical research organisation (CRO) with a global footprint, for an undisclosed sum.
China CRO Safe Pharma gets $71m Series D
Safe Pharmaceutical Research Institute, a Beijing-based clinic research organization (CRO) focused on novel drugs, has raised a CNY500m (USD 71m) Series D round led by SDIC Venture Capital and China State-owned Venture Capital Fund.
Fund focus: Panacea defies biotech downturn
Having raised its second fund amid weakening investor sentiment for biotech, Panacea Venture expects deployment to be guided by a widening valuation gap between the US and China
Panacea closes second healthcare fund on $276m
Panacea Venture, a healthcare-focused investment firm established by James Huang, formerly a partner at KPCB China, has closed its second fund with approximately USD 276m in commitments.
TPG completes buyout of Australia's iNova Pharmaceuticals
TPG has completed its acquisition of a majority stake in Australia-based prescription medicines business iNova Pharmaceuticals, facilitating exits for Pacific Equity Partners (PEP) and The Carlyle Group.
Deal focus: Elevation makes Korea healthcare debut
Adverse fundraising conditions didn’t deter deal-by-deal player Elevation Private Equity from investing in Korea healthcare turnaround, and by extension, aligning with a key domestic partner
VC-backed Singapore biotech start-up agrees SPAC merger
Singapore’s AUM Biosciences, a VC-backed oncology treatments developer, has agreed to a NASDAQ listing via special purpose acquisition company (SPAC) at a pre-money equity valuation of USD 400m.
Japan's NSSK buys Sakura pharmacy chain
Japanese middle-market private equity firm NSSK has acquired 100% of Kraft, a local pharmacy chain that operates under the Sakura brand, for an undisclosed sum.
China's VectorBuilder raises $57m Series C
Guangzhou-based gene delivery company VectorBuilder has raised a CNY 410m (USD 57m) Series C round led by Legend Capital, Sui Kai Equity Investment, and Yuexiu Industrial Fund.
China's Neushen Therapeutics gets $20m pre-Series A
China’s Neushen Therapeutics, a biotech developer focused on central nervous system (CNS) disorders, has raised USD 20m in pre-Series A funding led by local VC firm Lapam Capital.
Sequoia, ChrysCapital to exit India's Curatio
Sequoia Capital India and ChrysCapital Partners are set to exit Indian skincare brand Curatio, with Torrent Pharma agreeing to acquire 100% of the company for INR 20bn (USD 245m).
China drug developer Worg secures $57m Series B
Worg, a China-based drug developer, has closed a Series B round of CNY400m (USD57m) from five local investors - Jiachen Capital, Longpan Capital, Kaitai Capital, Puhua Capital and Anji Ruixing Capital.
PE-backed Mankind Pharma files for India IPO
Indian drug maker Mankind Pharma has filed for a domestic IPO, setting up an exit for Capital International, a private equity arm of Capital Group.
China's HighLight hits first close on life sciences fund, targets $650m
HighLight Capital, a China-based life sciences investor, has completed a first close of USD 540m on its fourth US dollar-denominated fund. The overall target is USD 650m.
Everstone buys India's Softgel Healthcare
Everstone Capital has acquired a controlling stake in Indian pharmaceuticals manufacturer Softgel Healthcare (SHPL) for an undisclosed sum.
China drug developer BoomRay gets $43m
Chinese drug developer BoomRay Pharmaceuticals has raised a CNY300m (USD 43m) Series A round led by Sequoia Capital China.
China cell therapy developer Neukio raises $50m
Shanghai-based cell therapy developer Neukio Biotherapeutics has raised USD 50m in the first tranche of a Series A round led by medical technology-focused CD Capital. Other new investors include Alwin Capital and Surplus Capital.
China Merchants Group backs CDMO player Porton Advanced
Three entities under China Merchants Group (CMG) have led a USD 80m Series B round for Porton Advanced Solutions, a local contract development and manufacturing organisation (CDMO) that focuses solely on gene and cell therapy services.
Quadria plans full exit through Concord Biotech's India IPO
Singapore-based healthcare specialist Quadria Capital is set for a full exit from pharmaceuticals industry supplier Concord Biotech via an India IPO.
China's Insilico Medicine gets another $35m
Insilico Medicine, a China-based artificial intelligence-driven drug discovery company, has closed the second tranche of its Series D round on USD 35m, with Prosperity7 Ventures taking the lead.
Navis exits medical cold chain player to US strategic
Navis Capital Partners has sold 100% of B Medical Systems, a Luxembourg-based biotech cold chain provider with significant Asian operations, at an enterprise value of EUR 460m (USD 469m).
Gaorong, Tsing Song back China CDMO IntellectiveBio
Gaorong Capital and Tsing Song Capital have led a CNY 500m (USD 74m) Series C for IntellectiveBio, a China-based contract development and manufacturing organisation (CDMO).
Morningside joins round for China's Epigenic Therapeutics
Morningside Venture Capital has teamed up with Kingray Capital, Trinity Innovation Fund, TigerYeah Capital, and FountainBridge Capital to provide USD 20m in angel and pre-Series A funding for Epigenic Therapeutics, a China-based gene editing specialist.
China biotech company GluBio raises $22m
China and US-based GluBio Therapeutics, which develops targeted protein degradation (TPD) drugs, has raised an extended Series A round of USD22m led by Qiming Venture Partners.